![Highlights from The California Cancer Consortium Conference 2024 by Sumanta K. Pal](https://oncodaily.com/pub/uploads/2023/09/Sumanta-Pal-1280x1280.jpeg)
Highlights from The California Cancer Consortium Conference 2024 by Sumanta K. Pal
The California Cancer Consortium Conference is an annual conference that brings together leading oncology experts, researchers, and clinicians to discuss the latest advancements in cancer research, treatment, and care.
The consortium often focuses on clinical trials, innovative therapies, and emerging research in oncology, with an emphasis on collaborative efforts to improve cancer treatment outcomes.
The conference typically serves as a platform for sharing the newest clinical data, particularly in areas like immunotherapy, targeted therapies, and personalized medicine, with the goal of advancing cancer care both regionally and nationally.
The California Cancer Consortium is a collaboration of institutions, such as City of Hope and other leading research hospitals and cancer centers across California, that are dedicated to improving cancer outcomes through clinical trials, research, and innovation.
Sumanta K. Pal shared about The California Cancer Consortium Conference 2024 on X:
“Always enjoy hearing Walter Stadler’s unique perspective on GU cancer drug development. One thing you can always count on from Walt – candor.”
“Go Abhishek Tripathi! Terrific overview of mCSPC, including updates on pivotal studies like CHAARTED (from his presentation at ASCO 22), PEACE, ARASENS, TITAN and more!”
“Great presentation from Mamta Parikh on mCRPC at CCCC24! Nice shoutout to Tanya Dorff’s CAR-T data in Nature Medicine, among other exciting data in the field.”
“A master class on Shuchi Gulati from UC Davis Comprehensive Cancer Center addressing adjuvant and metastatic kidney cancer. Very timely updates, even including Toni Choueiri and colleagues paper in NEJM this past week addressing belzutifan!”
“Tall task given to Tycel Phillips, having to summarize EVERYTHING heme in 15 min at CCCC24. From talquetamab in MM (Amrita Krishnan in NEJM 2022) to mosunetuzumab in FL (Elizabeth Budde in The Lancet Oncology 2022) to venetoclax in AML, he covered a wide range of topics beautifully. Amazing to see the footprint of City of Hope docs on these pivotal trials!”
For more posts by Sumanta K. Pal, visit oncodaily.com
Sumanta K. Pal is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the Vice Chair of Academic Affairs, Professor and co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.